ABBV

Abbvie Inc

195.22

6.20+3.28%

After Hours: 195.00 -0.22 -0.11%19:57 08/01 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE189.92/189.02

TODAY RANGE189.79-197.06

VOL8.08M

MARKET CAP344.84B

52 WEEK RANGE159.42-214.80

AVG VOL (3M)6.39M

% TURNOVER0.46%

TURNOVER--

P/E (TTM)83.24

% RANGE3.85%

EPS(TTM)2.345

P/E(FORWARD)28.67

P/B242.84

BVPS0.8039

DIVIDEND6.56

P/S6.12

BETA--

DIV YIELD3.36%

FREE FLOAT MKT CAP344.45B

SHARES OUTSTANDING1.77B

NEXT EARNINGS10/28-11/03

FREE FLOAT1.76B

LOT SIZE1

EX-DATE07/15/2025

News

Press Releases

Financial Reports

Profile

Seeking Alpha·9h ago
Key deals this week: Chart Industries, Northwind Midstream, AbbVie, Palo Alto Networks and more
The Motley Fool·18h ago
3 Unstoppable Stocks to Buy in August
NASDAQ·19h ago
3 Dividend Champion Stocks I'm Watching in 2025
TipRanks·1d ago
AbbVie Shines in Earnings Call with Strong Growth
Benzinga·1d ago
Expert Outlook: AbbVie Through The Eyes Of 4 Analysts
The Motley Fool·1d ago
Why AbbVie Stock Flew Higher on Friday
NASDAQ·1d ago
Friday Sector Leaders: Utilities, Healthcare
Simply Wall St·1d ago
AbbVie (ABBV) Reports Increased Sales But Lower Net Income For Q2 2025
Benzinga·1d ago
AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion
Benzinga·1d ago
Deal Dispatch: MEG Bidding War Heats Up, L Catterton Takes Bite Out Of Kisshokichi, Sunnova's Still Shining
Seeking Alpha·1d ago
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
TipRanks·1d ago
AbbVie’s Promising Phase 2 Study on Mirvetuximab Soravtansine for Ovarian Cancer
TipRanks·1d ago
AbbVie’s Ubrogepant Study: A New Hope for Menstrual Migraine Relief?
TipRanks·1d ago
AbbVie’s Promising Phase 3 Study on Etentamig for Multiple Myeloma
TipRanks·1d ago
AbbVie’s Real-World Study on Parkinson’s Treatment: A Potential Game Changer

Same Industry

Name/Symbol

Change%

Price

Abbvie Inc

ABBV

+3.28%

195.22

McKesson

MCK

+0.76%

698.80

Biogen Inc

BIIB

+3.09%

131.95

Amgen Inc

AMGN

+0.60%

296.88

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

0.00%

0.0301

Shire

SHPG

179.20

Celgene

CELG

108.24

Lilly Eli & Co

LLY

+3.01%

762.33

Therapeuticsmd Inc

TXMD

-0.89%

1.11

Johnson & Johnson

JNJ

+1.57%

167.33

Zoetis Inc

ZTS

+1.09%

147.38

Gilead Sciences Inc

GILD

+0.79%

113.18

Novo-Nordisk A/S

NVO

+2.38%

48.19

Bristol-Myers Squibb Co

BMY

+2.12%

44.23

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

+0.86%

23.49

Sanofi FR

SNY

+2.43%

46.75

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

+1.37%

115.30

Dr Reddys Labs

RDY

-1.97%

13.94

GSK PLC

GSK

+1.10%

37.56

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English